دورية أكاديمية
Whole brain radiotherapy with radiosensitizer for brain metastases.
| العنوان: | Whole brain radiotherapy with radiosensitizer for brain metastases. |
|---|---|
| المؤلفون: | Viani GA; Department of Radiation Oncology at Marilia Medicine School, São Paulo, Brazil. gusviani@gmail.com, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ |
| المصدر: | Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2009 Jan 06; Vol. 28, pp. 1. Date of Electronic Publication: 2009 Jan 06. |
| نوع المنشور: | Journal Article; Meta-Analysis |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2009- : London : BioMed Central Original Publication: [Roma] : APSIT, |
| مواضيع طبية MeSH: | Brain Neoplasms/*radiotherapy , Brain Neoplasms/*secondary , Cranial Irradiation/*methods , Radiation-Sensitizing Agents/*therapeutic use, Adult ; Combined Modality Therapy ; Disease Progression ; Dose Fractionation, Radiation ; Humans ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Treatment Outcome |
| مستخلص: | Purpose: To study the efficacy of whole brain radiotherapy (WBRT) with radiosensitizer in comparison with WBRT alone for patients with brain metastases in terms of overall survival, disease progression, response to treatment and adverse effects of treatment. Methods: A meta-analysis of randomized controlled trials (RCT) was performed in order to compare WBRT with radiosensitizer for brain metastases and WBRT alone. The MEDLINE, EMBASE, LILACS, and Cochrane Library databases, in addition to Trial registers, bibliographic databases, and recent issues of relevant journals were researched. Significant reports were reviewed by two reviewers independently. Results: A total of 8 RCTs, yielding 2317 patients were analyzed. Pooled results from this 8 RCTs of WBRT with radiosensitizer have not shown a meaningful improvement on overall survival compared to WBRT alone OR = 1.03 (95% CI0.84-1.25, p = 0.77). Also, there was no difference in local brain tumor response OR = 0.8(95% CI 0.5 - 1.03) and brain tumor progression (OR = 1.11, 95% CI 0.9 - 1.3) when the two arms were compared. Conclusion: Our data show that WBRT with the following radiosentizers (ionidamine, metronidazole, misonodazole, motexafin gadolinium, BUdr, efaproxiral, thalidomide), have not improved significatively the overall survival, local control and tumor response compared to WBRT alone for brain metastases. However, 2 of them, motexafin- gadolinium and efaproxiral have been shown in recent publications (lung and breast) to have positive action in lung and breast carcinoma brain metastases in association with WBRT. |
| References: | N Engl J Med. 1990 Feb 22;322(8):494-500. (PMID: 2405271) Ann Neurol. 1980 Jun;7(6):529-41. (PMID: 7436358) Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5. (PMID: 7513432) Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):53-8. (PMID: 1993631) Expert Rev Anticancer Ther. 2004 Dec;4(6):981-9. (PMID: 15606327) Int J Cancer. 2001 May 15;92(4):510-7. (PMID: 11304685) Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78. (PMID: 15863032) J Clin Oncol. 2003 Jun 15;21(12):2364-71. (PMID: 12805339) Semin Radiat Oncol. 1996 Jan;6(1):10-21. (PMID: 10717158) J Clin Oncol. 2006 Jan 1;24(1):106-14. (PMID: 16314619) Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34. (PMID: 10487566) Cancer Metastasis Rev. 2007 Jun;26(2):341-52. (PMID: 17415529) J Neurooncol. 1989 Sep;7(3):241-7. (PMID: 2677257) JAMA. 1998 Nov 4;280(17):1485-9. (PMID: 9809728) Oncology (Williston Park). 2000 Jan;14(1):75-9; discussion 79, 81-2, 85. (PMID: 10680150) Cancer. 1981 Jul 15;48(2):384-94. (PMID: 7237407) Cancer Treat Rev. 2005 Jun;31(4):256-73. (PMID: 15951117) Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):743-50. (PMID: 15701864) Am J Physiol. 1996 Aug;271(2 Pt 2):H602-13. (PMID: 8770102) Control Clin Trials. 1996 Feb;17(1):1-12. (PMID: 8721797) J Clin Oncol. 2002 Sep 1;20(17):3644-50. (PMID: 12202665) Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9. (PMID: 6154024) Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51. (PMID: 9128946) Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):83-9. (PMID: 16213107) Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76. (PMID: 18977094) Int J Radiat Oncol Biol Phys. 1981 Jul;7(7):891-5. (PMID: 6171553) J Neurooncol. 1984;2(4):325-30. (PMID: 6397578) J Clin Oncol. 2001 Apr 1;19(7):2074-83. (PMID: 11283141) Nat Rev Cancer. 2004 Jun;4(6):437-47. (PMID: 15170446) Lancet Oncol. 2002 Dec;3(12):728-37. (PMID: 12473514) Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):339-48. (PMID: 7673021) Am J Clin Oncol. 2007 Dec;30(6):580-7. (PMID: 18091051) J Clin Oncol. 2003 Jul 1;21(13):2529-36. (PMID: 12829672) Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. (PMID: 18164847) Expert Opin Investig Drugs. 2004 May;13(5):543-50. (PMID: 15155129) Int J Cancer. 1994 Jun 15;57(6):920-5. (PMID: 7515861) Cancer Res. 2000 Oct 1;60(19):5565-70. (PMID: 11034104) Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1133-9. (PMID: 11240256) |
| المشرفين على المادة: | 0 (Radiation-Sensitizing Agents) |
| تواريخ الأحداث: | Date Created: 20090108 Date Completed: 20090826 Latest Revision: 20211020 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC2648943 |
| DOI: | 10.1186/1756-9966-28-1 |
| PMID: | 19126230 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1756-9966 |
|---|---|
| DOI: | 10.1186/1756-9966-28-1 |